In patient 1, SPINK1 was identified in all 3 CTCs analyzed, and accumulating evidence suggests this defines a subtype of prostate cancer that is susceptible to therapies targeting SPINK1 or EGFR (cetuximab) [30]. The gene discussed is SPINK1; the disease is prostate cancer.